Characterization of ERK Docking Domain Inhibitors that Induce Apoptosis by Targeting Rsk-1 and Caspase-9

<p>Abstract</p> <p>Background</p> <p>The extracellular signal-regulated kinase-1 and 2 (ERK1/2) proteins play an important role in cancer cell proliferation and survival. ERK1/2 proteins also are important for normal cell functions. Thus, anti-cancer therapies that bloc...

Full description

Bibliographic Details
Main Authors: MacKerell Alexander D, Priyakumar U Deva, Strome Scott, Deshmukh Rahul, Boston Sarice R, Shapiro Paul
Format: Article
Language:English
Published: BMC 2011-01-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/11/7
id doaj-48e0feec40ce4184a20e9d2fa2191e18
record_format Article
spelling doaj-48e0feec40ce4184a20e9d2fa2191e182020-11-24T23:58:56ZengBMCBMC Cancer1471-24072011-01-01111710.1186/1471-2407-11-7Characterization of ERK Docking Domain Inhibitors that Induce Apoptosis by Targeting Rsk-1 and Caspase-9MacKerell Alexander DPriyakumar U DevaStrome ScottDeshmukh RahulBoston Sarice RShapiro Paul<p>Abstract</p> <p>Background</p> <p>The extracellular signal-regulated kinase-1 and 2 (ERK1/2) proteins play an important role in cancer cell proliferation and survival. ERK1/2 proteins also are important for normal cell functions. Thus, anti-cancer therapies that block all ERK1/2 signaling may result in undesirable toxicity to normal cells. As an alternative, we have used computational and biological approaches to identify low-molecular weight compounds that have the potential to interact with unique ERK1/2 docking sites and selectively inhibit interactions with substrates involved in promoting cell proliferation.</p> <p>Methods</p> <p>Colony formation and water soluble tetrazolium salt (WST) assays were used to determine the effects of test compounds on cell proliferation. Changes in phosphorylation and protein expression in response to test compound treatment were examined by immunoblotting and <it>in vitro </it>kinase assays. Apoptosis was determined with immunoblotting and caspase activity assays.</p> <p>Results</p> <p><it>In silico </it>modeling was used to identify compounds that were structurally similar to a previously identified parent compound, called <b>76</b>. From this screen, several compounds, termed <b>76.2</b>, <b>76.3</b>, and <b>76.4 </b>sharing a common thiazolidinedione core with an aminoethyl side group, inhibited proliferation and induced apoptosis of HeLa cells. However, the active compounds were less effective in inhibiting proliferation or inducing apoptosis in non-transformed epithelial cells. Induction of HeLa cell apoptosis appeared to be through intrinsic mechanisms involving caspase-9 activation and decreased phosphorylation of the pro-apoptotic Bad protein. Cell-based and <it>in vitro </it>kinase assays indicated that compounds <b>76.3 </b>and <b>76.4 </b>directly inhibited ERK-mediated phosphorylation of caspase-9 and the p90Rsk-1 kinase, which phosphorylates and inhibits Bad, more effectively than the parent compound <b>76</b>. Further examination of the test compound's mechanism of action showed little effects on related MAP kinases or other cell survival proteins.</p> <p>Conclusion</p> <p>These findings support the identification of a class of ERK-targeted molecules that can induce apoptosis in transformed cells by inhibiting ERK-mediated phosphorylation and inactivation of pro-apoptotic proteins.</p> http://www.biomedcentral.com/1471-2407/11/7
collection DOAJ
language English
format Article
sources DOAJ
author MacKerell Alexander D
Priyakumar U Deva
Strome Scott
Deshmukh Rahul
Boston Sarice R
Shapiro Paul
spellingShingle MacKerell Alexander D
Priyakumar U Deva
Strome Scott
Deshmukh Rahul
Boston Sarice R
Shapiro Paul
Characterization of ERK Docking Domain Inhibitors that Induce Apoptosis by Targeting Rsk-1 and Caspase-9
BMC Cancer
author_facet MacKerell Alexander D
Priyakumar U Deva
Strome Scott
Deshmukh Rahul
Boston Sarice R
Shapiro Paul
author_sort MacKerell Alexander D
title Characterization of ERK Docking Domain Inhibitors that Induce Apoptosis by Targeting Rsk-1 and Caspase-9
title_short Characterization of ERK Docking Domain Inhibitors that Induce Apoptosis by Targeting Rsk-1 and Caspase-9
title_full Characterization of ERK Docking Domain Inhibitors that Induce Apoptosis by Targeting Rsk-1 and Caspase-9
title_fullStr Characterization of ERK Docking Domain Inhibitors that Induce Apoptosis by Targeting Rsk-1 and Caspase-9
title_full_unstemmed Characterization of ERK Docking Domain Inhibitors that Induce Apoptosis by Targeting Rsk-1 and Caspase-9
title_sort characterization of erk docking domain inhibitors that induce apoptosis by targeting rsk-1 and caspase-9
publisher BMC
series BMC Cancer
issn 1471-2407
publishDate 2011-01-01
description <p>Abstract</p> <p>Background</p> <p>The extracellular signal-regulated kinase-1 and 2 (ERK1/2) proteins play an important role in cancer cell proliferation and survival. ERK1/2 proteins also are important for normal cell functions. Thus, anti-cancer therapies that block all ERK1/2 signaling may result in undesirable toxicity to normal cells. As an alternative, we have used computational and biological approaches to identify low-molecular weight compounds that have the potential to interact with unique ERK1/2 docking sites and selectively inhibit interactions with substrates involved in promoting cell proliferation.</p> <p>Methods</p> <p>Colony formation and water soluble tetrazolium salt (WST) assays were used to determine the effects of test compounds on cell proliferation. Changes in phosphorylation and protein expression in response to test compound treatment were examined by immunoblotting and <it>in vitro </it>kinase assays. Apoptosis was determined with immunoblotting and caspase activity assays.</p> <p>Results</p> <p><it>In silico </it>modeling was used to identify compounds that were structurally similar to a previously identified parent compound, called <b>76</b>. From this screen, several compounds, termed <b>76.2</b>, <b>76.3</b>, and <b>76.4 </b>sharing a common thiazolidinedione core with an aminoethyl side group, inhibited proliferation and induced apoptosis of HeLa cells. However, the active compounds were less effective in inhibiting proliferation or inducing apoptosis in non-transformed epithelial cells. Induction of HeLa cell apoptosis appeared to be through intrinsic mechanisms involving caspase-9 activation and decreased phosphorylation of the pro-apoptotic Bad protein. Cell-based and <it>in vitro </it>kinase assays indicated that compounds <b>76.3 </b>and <b>76.4 </b>directly inhibited ERK-mediated phosphorylation of caspase-9 and the p90Rsk-1 kinase, which phosphorylates and inhibits Bad, more effectively than the parent compound <b>76</b>. Further examination of the test compound's mechanism of action showed little effects on related MAP kinases or other cell survival proteins.</p> <p>Conclusion</p> <p>These findings support the identification of a class of ERK-targeted molecules that can induce apoptosis in transformed cells by inhibiting ERK-mediated phosphorylation and inactivation of pro-apoptotic proteins.</p>
url http://www.biomedcentral.com/1471-2407/11/7
work_keys_str_mv AT mackerellalexanderd characterizationoferkdockingdomaininhibitorsthatinduceapoptosisbytargetingrsk1andcaspase9
AT priyakumarudeva characterizationoferkdockingdomaininhibitorsthatinduceapoptosisbytargetingrsk1andcaspase9
AT stromescott characterizationoferkdockingdomaininhibitorsthatinduceapoptosisbytargetingrsk1andcaspase9
AT deshmukhrahul characterizationoferkdockingdomaininhibitorsthatinduceapoptosisbytargetingrsk1andcaspase9
AT bostonsaricer characterizationoferkdockingdomaininhibitorsthatinduceapoptosisbytargetingrsk1andcaspase9
AT shapiropaul characterizationoferkdockingdomaininhibitorsthatinduceapoptosisbytargetingrsk1andcaspase9
_version_ 1725448839834370048